Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors Amgen; MedImmune

    • Most Recent Events

    • 01 May 2024 Results of pooled analysis from pooled analysis of the PATHWAY study will be presented at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
    • 07 Nov 2023 Results of pooled analysis from pooled analysis of the PATHWAY and NAVIGATOR , published in the Annals of Internal Medicine
    • 13 Sep 2023 Results of post-hoc pooled analysis from PATHWAY (NCT02054130) and NAVIGATOR(NCT03347279) studies assessing the effect of tezepelumab on pre-BD ppFEV1 in patients grouped by baseline pre-BD ppFEV1 presented at the 33rd Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top